CARDIFF ONCOLOGY INC. - COMMON STOCK

4.1600

10-July-25 13:45:00

15 minutes delayed

Stocks

+0.0800

+1.96%

Today's range

4.0200 - 4.2000

ISIN

N/A

Source

NASDAQ

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

08 Apr 2024 13:05:00 By Nasdaq GlobeNewswire
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

06 Mar 2024 13:05:00 By Nasdaq GlobeNewswire
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

29 Feb 2024 13:07:00 By Nasdaq GlobeNewswire
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

29 Feb 2024 13:06:00 By Nasdaq GlobeNewswire
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

29 Feb 2024 13:05:00 By Nasdaq GlobeNewswire
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

26 Feb 2024 05:00:00 By Nasdaq GlobeNewswire
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

22 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.